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Abstract
Background: Oral leukoplakia is a precancerous change developed in the oral mucosa, and the
mechanism that oral leukoplakia becomes malignant through atypical epithelium is not known. Here
we compared the β-catenin expression detected by immunohistochemical staining in the normal
oral epithelium and in the oral leukoplakia with or without dysplasia.
Results: The normal oral epithelium showed β-catenin expression only in the cell membrane, but
not in the nuclei. In the oral leukoplakia without dysplasia, 7 out of 17 samples (41%) showed β-
catenin expression in the cell membrane, and 5 samples (29%) showed expression in the nuclei. In
the oral leukoplakia with dysplasia, nuclear expression of β-catenin was shown in 11 out of 12
samples (92%). Incidence of nuclear β-catenin expression was significantly different between
dysplasia and normal oral epithelium (P < 0.01), and also between oral leukoplakia with dysplasia
and those without dysplasia (P < 0.01). Wnt3 expression was detected in the epithelial cell
membrane or cytoplasm in oral leukoplakia where nuclear expression of β-catenin was evident, but
not in epithelial cells without nuclear expression of β-catenin.
Conclusion: The components of canonical Wnt pathway, such as Wnt3, β-catenin, and cyclin D1,
were detected, implying that this pathway is potentially involved in the progression of dysplasia in
oral leukoplakia.
Background
Oral leukoplakia is known as a precancerous change of
squamous cell carcinoma developed in oral mucosa [1-3].
Leukoplakia is a term expressing clinical disease state, and
it occurs in every intra-oral locus and shows various obser-
vations. Because a clinician is difficult to be settled with
precancerous lesion in these, we require histopathology
examination. Leukoplakia diagnosed as epithelial dyspla-
sia histopathology in leukoplakia becomes precancerous.
It is said that it may become malignant transformation in
progression of the severity in epithelial dysplasia [4].
Although much works have been done on the leukopla-
kia, the mechanism that oral mucosa epithelium consti-
tuting leukoplakia becomes malignant through atypical
epithelium is not known.
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There are many reports on β-catenin accumulation into a
nucleus of a cancer cell in the epithelial malignant tumor,
including colorectal cancer [5-8], and transcription activa-
tion of a target gene by β-catenin/TCF is known to partic-
ipate in malignant transformation [9,10]. Transcription
activation by β-catenin is triggered by binding of Wnt fam-
ily to the cell membrane receptors, called Frizzled and
LRP5/6, which transduces Wnt signal inside the cell
through inactivation of GSK-3. APC and Axin constitute a
complex to phosphorylate β-catenin with GSK-3. In the
presence of Wnt, the receptor complex transduces nega-
tive signals to APC/Axin/GSK-3 complex through Dishev-
elled, and thus GSK-3 becomes unable to phosphorylate
cellular β-catenin. Accumulated β-catenin in cytoplasm is
now translocated into a nucleus, forms a transcriptional
activation complex with TCF/LEF1 [10-13], and activates
various target genes such as c-myc and cyclin D1 [14-17].
In the absence of Wnt, β-catenin in cytoplasm is immedi-
ately phosphorylated by GSK-3/Axin/APC complex and
receives ubiquitination, eventually leading to degradation
in proteasome, and thus disappeared in cytoplasm imme-
diately [9,10].
Because Wnt family is known to participate in epithelial
cell proliferation, we examined in this study immunohis-
tochemical localization of β-catenin, with attention to
transcription activation of a target gene by β-catenin, and
to evaluate nuclear accumulation β-catenin in relevance
with atypical epithelium in a surface layer of oral leuko-
plakia. Nuclear localization of β-catenin is correlated with
cyclin D1 expression in oral leukoplakia, and also Wnt3
expression in neighboring cells, known as a typical mem-
ber of the Wnt family that activates β-catenin-mediated
signaling [18,19], suggesting the involvement of Wnt/β-
catenin signaling in the progression of dysplasia.
Results
Immunohistochemical localization of β-catenin
The expression patterns of β-catenin in oral mucosa are
summarized in Table 1. In the normal oral epithelium,
nuclear localization of β-catenin was not detected in all 6
samples examined; 5 out of 6 samples showed expression
signals only in the cell membrane, and one sample
showed cytoplasmic expression in addition to signals in
the cell membrane. In the oral leukoplakia without dys-
plasia, 7 out of 17 samples (41%) showed expression sig-
nals in the cell membrane, and 5 samples (29%) showed
expression signals in the nuclei. Oral leukoplakia with
dysplasia did not show expression signals in the cell mem-
brane, and nuclear expression was shown in 11 out of 12
samples (92%).
Localization of β-catenin in the epithelial cell membranes
was observed in normal oral epithelium and oral leuko-
plakia, whereas expression in OSCC was low or totally
absent in the cell membrane (Fig. 1). The expression of β-
catenin in normal oral epithelium was observed on the
cell membrane, but not within the nuclei of basal and
spinous layer (Fig. 1b, 1c). In oral leukoplakia without
dysplasia, the expression of β-catenin was observed on the
cell membrane or both cell membrane and cytoplasm in
24% of basal and spinous layer cells (Fig. 1e, 1f). In oral
leukoplakia with mild dysplasia, the expression of β-cat-
enin was observed in the nuclei at about 30% (Fig. 1h, 1i).
Oral leukoplakia with dysplasia that was especially char-
acterized by an increased nuclear-cytoplasmic ratio, an
increased number of mitotic figures, including abnormal
mitoses, nuclear hyperchromatism showed nuclear
expression pattern (Fig. 1k, 1l), and the expression of β-
catenin in nuclei was shown in more than 80% of epithe-
lial cells. The mean percentage of nuclear staining with β-
catenin in oral leukoplakia is presented in Table 2. The
nuclear expression of β-catenin in epithelial dysplasia
increased depending on the grade of dysplasia, and there
were significantly different between β-catenin staining
without dysplasia and that with mild dysplasia (P < 0.01),
and also between β-catenin staining with mild dysplasia
and that with severe dysplasia (P < 0.05). The tumor
parenchymal cells of OSCC (Fig. 1m–o) also showed
nuclear expression pattern in 10 out of 15 specimens
(67%). Incidence of nuclear localization of β-catenin was
significantly different between dysplasia and normal oral
epithelium (P < 0.01), and also between oral leukoplakia
with dysplasia and those without dysplasia (P < 0.01).
Table 1: Expression patterns of β-catenin in oral mucosa
Tissue Total number Cytoplasm Nucleus Membrane
Normal oral epithelium 6 1 0 5
Oral leukoplakia
Without dysplasia 17 5 5 7
With dysplasia 12 1 11* 0
Oral squamous cell carcinoma 15 5 10 0
*P < 0.01 between normal oral epithelium and oral leukoplakia without dysplasia by Fisher's exact test.Molecular Cancer 2007, 6:62 http://www.molecular-cancer.com/content/6/1/62
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Relationship between localization of β-catenin and Wnt3 
expression
We examined the expression pattern of Wnt3 in oral leu-
koplakia. Wnt3 was not expressed in the normal oral epi-
thelium (data not shown). Figure 2 shows comparison of
immunohistochemical staining for β-catenin, Wnt3, cyc-
lin D1, and c-myc in oral leukoplakia without dysplasia
(a-d) and those with dysplasia (e-l). Wnt3 was expressed
on the epithelial cell membrane or cytoplasm where
nuclear expression of β-catenin is evident, in contrast to
those without nuclear expression of β-catenin (Fig. 2b, 2f,
2j). In the samples with nuclear expression of β-catenin,
Wnt3 expression was shown in 13 out of 16 samples
(81%), and there is significant positive correlation
between the nuclear expression of β-catenin and Wnt3
staining (P < 0.01) (Table 3).
We also examined other members of Wnt family, includ-
ing Wnt1, Wnt5a, and Wnt7a, for immunohistochemical
staining. No signal was detectable with antibodies against
Wnt1 and Wnt7a in normal and leukoplakia epithelia,
whereas Wnt5a signal was ubiquitously detectable in nor-
mal oral epithelium, leukoplakia, and in OSCC (data not
shown). Thus, these Wnt members are unlikely to be
involved in nuclear localization of β-catenin because of
the absence of correlation.
Relationship with cyclin D1 and c-myc expression
Cyclin D1 was intensely expressed in the oral leukoplakia
where nuclear expression of β-catenin is evident, in con-
trast to those without nuclear expression of β-catenin (Fig.
2). Cyclin D1 overexpression was more evident in the oral
leukoplakia with dysplasia than that without dysplasia
(Fig. 2c, 2g, 2k), and percentage of the cell number with
positive nuclear staining is significantly different in these
specimens (Fig. 3). On the other hand, the c-myc expres-
Table 2: Mean percentage of nuclear β-catenin staining in oral 
leukoplakia with and without dysplasia
Pathological diagnosis Total number Positive ratio (mean value)
No dysplasia 17 6.7
Mild dysplasia 9 26.9*
Severe dysplasia 3 59.7**
*P < 0.01 between no dysplasia samples and mild dysplasia samples by 
Student's t-test.
**P < 0.05 between mild dysplasia samples and severe dysplasia 
samples by Student's t-test.
Immunohistochemical localization of β-catenin in normal oral epithelium (a-c), oral leukoplakia without dysplasia (d-f), oral leu- koplakia with mild dysplasia (g-i), oral leukoplakia with severe dysplasia (j-l), and oral squamous cell carcinoma (m-o) Figure 1
Immunohistochemical localization of β-catenin in normal oral epithelium (a-c), oral leukoplakia without dysplasia (d-f), oral leu-
koplakia with mild dysplasia (g-i), oral leukoplakia with severe dysplasia (j-l), and oral squamous cell carcinoma (m-o). (a, d, g, j) 
Hematoxylin and eosin staining. (b, c, e, f, h, i, k, l, m-o) β-Catenin staining. (b, c) Signals were detected in the cell membrane of 
the basal and spinous layer, but not in the cytoplasm and nuclei. (e, f) Signals were detected in the cell membranes and cyto-
plasm. (h, i) Signals were detected in the cell membranes and nuclei. (j) The area for dysplasia is characterized by an increased 
nuclear-cytoplasmic ratio, an increased number of mitotic figures, including abnormal mitoses, nuclear hyperchromatism. (k, l) 
Signals were detected in the cell membranes and nuclei. (m-o) Signals were detected in the nucleus of the epithelial dysplastic 
cells (n) and carcinoma cells (o) in OSCC, but cell membranous expression was weak or absent. Scale bars: (a, b, d, e, g, h, j, k, 
m) 200 µm; (c, f, i, l, n, o) 50 µm.Molecular Cancer 2007, 6:62 http://www.molecular-cancer.com/content/6/1/62
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Comparison of immunohistochemical staining for β-catenin, Wnt3, cyclin D1, and c-myc in oral leukoplakia Figure 2
Comparison of immunohistochemical staining for β-catenin, Wnt3, cyclin D1, and c-myc in oral leukoplakia. (a-d) Serial sec-
tions of oral leukoplakia without dysplasia. (a) Nuclear expression of β-catenin was not observed. (b) Wnt3 expression was 
not observed. (c) Cyclin D1 shows weak expression. (d) Nuclear expression of c-myc is observed in the basal layer cells. (e-h) 
Serial sections of oral leukoplakia with dysplasia. (e, i) β-Catenin is expressed in the nuclei. (f, j) Wnt3 expression is observed 
on the epithelial cell membrane and in the cytoplasm. (g, k) Cyclin D1 is expressed in several epithelial cells. (h, l) c-Myc shows 
similar expression pattern as oral leukoplakia without dysplasia. Scale bars: (a-h) 100 µm; (i-l) 50 µm.Molecular Cancer 2007, 6:62 http://www.molecular-cancer.com/content/6/1/62
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sion in nuclei was not significantly different between
these two specimens (Fig. 2d, 2h, 2l), suggesting inde-
pendent activation of c-myc.
Discussion
β-Catenin has been identified to be a constituent of cell
adhesion apparatus bound to cadherin family [20], and
plays an important role for cellular movement and adhe-
sion, as well as a signaling factor involved in canonical
Wnt pathway [9]. Nuclear localization of β-catenin is
known to associate with malignant transformation of
colorectal cancer and other tumor [5-8]. Because cytoplas-
mic accumulation and subsequent nuclear translocation
of β-catenin is known to be resulted from activation of
canonical Wnt signaling pathways [10], subcellular local-
ization of β-catenin is a useful marker to detect cellular
conditions to proliferate actively. We compared here
immunohistochemical localization of β-catenin in the
normal oral epithelia, oral leukoplakia, and OSCC, aimed
at elucidating relationship between proliferative activity
and subcellular localization of the products.
In contrast to membranous and cytoplasmic expression,
nuclear expression of β-catenin is implicated in tumor
progression, but the significance of β-catenin localization
in the oral epithelial dysplasia and OSCC has not yet been
examined in details. The nuclear expression of β-catenin
increased during progression of the severity in oral leuko-
plakia. Furthermore, because localization of β-catenin in
normal oral epithelium and dysplasia showed significant
difference, suggesting nuclear expression of β-catenin as
aberrant condition. In addition, nuclear expression of β-
catenin was also observed in 10 out of 15 samples of
OSCC, and membranous β-catenin expression was low or
totally absent in 7 out of 15 samples of OSCC (data not
shown). In various malignant tumors, reduced membra-
nous β-catenin expression was associated with the emer-
gence of invasion or metastasis [21-24]. Our results
suggest that β-catenin function in cell-cell adhesion and
translocation in the nucleus are related to proliferation
and invasion of OSCC.
c-Myc and cyclin D1 have been identified as target genes
of the Wnt/β-catenin pathway [14-17]. Tetsu and McCor-
mick [25] reported that expression of cyclin D1 is strongly
dependent on β-catenin/TCF and has a direct effect on cell
proliferation in colon carcinoma cells. Furthermore,
Kovesi and Szende [26] reported that expression of cyclin
D1 increased during progression of the severity in oral
leukoplakia. Our results showed elevated cyclin D1
expression in the epithelial dysplasia. In oral epithelium,
cyclin D1 may participate in malignant transformation. c-
Myc expression was elevated in dysplasia with nuclear
expression of β-catenin than that without nuclear expres-
sion, although the difference in c-myc expression is not
evident.
Our studies show the aberrant Wnt signaling pathway in
the oral epithelial dysplasia. Wnt3, a typical member of
the Wnt family that activates β-catenin mediated signaling
[18,19], was not expressed in the normal oral epithelium.
In contrast, Wnt3 expression was observed in the exam-
ples showing nuclear expression of β-catenin. Both the
nuclear expression of β-catenin and Wnt3 expression were
observed in oral leukoplakia with dysplasia, and therefore
the aberrant Wnt signaling pathway may promote malig-
nant transformation by triggering cyclin D1 expression
and consequently uncontrolled progression into the cell
cycle.
These lines of evidence suggest that nuclear accumulation
of β-catenin plays an important role during malignant
transition of oral leukoplakia through dysplasia. In addi-
Table 3: Relationship between nuclear expression of β-catenin 
and Wnt3 expression in oral leukoplakia
β-Catenin Total number Wnt3
-+
Nuclear expression negative 13 10 3 (23.1%)
Nuclear expression positive 16 3 13 (81.3%)*
*P < 0.01 between nuclear expression negative and positive samples 
by Mann-Whitney U-test.
Relationship between subcellular localization of β-catenin and  expression patterns of cyclin D1 and c-myc in oral leukopla- kia Figure 3
Relationship between subcellular localization of β-catenin and 
expression patterns of cyclin D1 and c-myc in oral leukopla-
kia. Shown by means with standard deviations.Molecular Cancer 2007, 6:62 http://www.molecular-cancer.com/content/6/1/62
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tion to pathological examination of hematoxylin and
eosin-stained sections for oral leukoplakia, immuno-
chemical staining for β-catenin is useful for diagnosis of
epithelial dysplasia and precancerous changes. Evaluation
of other constituents for Wnt signaling, including GSK-3,
CDK, Frizzled, and LRP5/6, helps us for determination
and prognosis of precancerous change of dysplasia.
Conclusion
As for the transcriptional activation of a target gene by β-
catenin, elevated expression was detected in a squamous
cell carcinoma and epithelial dysplasia of oral leukopla-
kia. Thus, Wnt/β-catenin pathway is considered to be
involved in the progression of dysplasia in oral leukopla-
kia, as shown by nuclear expression of β-catenin and other
components, including Wnt3 and cyclin D1.
Methods
Tissue samples
Formalin-fixed, paraffin-embedded samples of normal
oral mucosa (6 examples), of oral squamous cell carci-
noma (15 examples), and of oral leukoplakia (29 exam-
ples) were used. A fresh tissue of the oral cavity is also
obtained at the time of biopsy or at oral surgery during
treatment of cancerous disease after obtaining informed
consent to the patients, and fixed in formalin before par-
affin embedding. A histopathological diagnosis of each
sample was performed by pathological staffs in the
Department of Pathology in Kawasaki Medical School
Hospital. According to the WHO diagnostic criteria for
histological typing of cancer and pre-cancer of the oral
mucosa [1], 12 examples from oral leukoplakia were diag-
nosed as epithelial dysplasia lesion (dysplasia). Dysplasia
was diagnosed and graded as mild dysplasia (9 examples)
and severe dysplasia (3 examples).
Immunohistochemistry
Sections of 4 µm thickness in paraffin embedding tissue
were treated with microwave for 10 minutes in 10 mM cit-
rate buffer (pH 6) after de-paraffin processing, followed
by washing with PBS twice for 10 minutes. To remove
endogenous peroxidase activity, sections were treated in
3% hydrogen peroxide solution for 15 minutes, and sub-
sequently in PBS twice for five minutes. The primary anti-
bodies against β-catenin (Sigma-Aldrich), Wnt3 (Santa
Cruz Biotechnology), cyclin D1 (Zymed Laboratories),
and c-myc (Santa Cruz Biotechnology) were used at 1/
400, 1/100, 1/50, and 1/50 dilution, respectively, in PBS
by incubating at room temperature for 60 min. After
washing with PBS, the sections were treated with bioti-
nylated secondary antibody for 10 min and then with per-
oxidase-labeled streptavidin for 10 min (LSAB PLUS kit,
DAKO, Japan), and the color was developed with 3,3'-
diaminobenzidine tetrahydrochloride (LSAB PLUS kit,
DAKO, Japan), followed by counter staining with Mayer's
hematoxylin. As a negative control, primary antibodies
were omitted and the sections were incubated with the
secondary antibody alone.
Evaluation of staining
For counting cells with nuclear and/or cytoplasm staining,
three microscopic fields with 200-fold magnification were
randomly chosen and the mean above 10% of the total
cell numbers was deduced to be positive.
Evaluation of staining was carried out based on whether
nuclear or cytoplasmic staining is detectable. Under
microscopic field of 200-fold magnification, tissues are
positive for β-catenin, if more than 10% of cells show
cytoplasmic or nuclear staining. Randomly selected field
in the tumor parenchymal region was used for determina-
tion of β-catenin positive cells in squamous cell carci-
noma. Because signal intensity and distribution were
different depending on the places in leukoplakia without
dysplasia and in the normal oral epithelium, three fields
were randomly selected to determine average ratio of a
positive cell. In the Wnt3 staining, the cell membranous
or cytoplasmic staining in the basal and spinous layer was
regarded as positive. For cyclin D1 and c-myc, nuclear
staining was regarded as positive. The cyclin D1 and c-myc
staining was evaluated by counting at 200-fold magnifica-
tion and calculating the percentage of positive cells. Statis-
tical significance was estimated using Fisher's exact test,
Mann-Whitney U-test, and Student's t-test.
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